Wells Fargo Maintains Bluebird Bio(BLUE.US) With Hold Rating, Maintains Target Price $2
Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), Bluebird Bio (BLUE) and AC Immune SA (ACIU)
Bluebird Bio Is Maintained at Overweight by Barclays
Bluebird Bio Analyst Ratings
A Quick Look at Today's Ratings for Bluebird Bio(BLUE.US), With a Forecast Between $0.5 to $2
Bluebird Bio Downgraded to Underweight From Neutral at JPMorgan
J.P. Morgan Maintains Bluebird Bio(BLUE.US) With Hold Rating
Bluebird Bio's Restructuring Efforts and Financial Outlook: A Cautious Hold Rating
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
Bluebird Bio Analyst Ratings
Wells Fargo Maintains Bluebird Bio(BLUE.US) With Hold Rating, Cuts Target Price to $2
Maintaining Hold on Bluebird Bio: Balancing LYFGENIA's Promise Against Financial and Operational Hurdles
Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $4
Analysts Are Bullish on Top Healthcare Stocks: Bluebird Bio (BLUE), Immunic (IMUX)
William Blair Maintains Bluebird Bio(BLUE.US) With Hold Rating
William Blair Reaffirms Their Hold Rating on Bluebird Bio (BLUE)
Bluebird Bio Analyst Ratings
J.P. Morgan Maintains Bluebird Bio(BLUE.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)
What 4 Analyst Ratings Have To Say About Bluebird Bio